Back

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Renal failure and cardiovascular disease 2 Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ajay Singh

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial
Doctor K. Mahaffey (Stanford, US)
Abstract Slides
Presentation thumbnail
Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
Ms A. Pettersson Meyer (DK)
Abstract Slides
Presentation thumbnail
CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD
Doctor B. Rocha (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy
Ms J. Boen (Antwerp, BE)
Abstract Slides
Presentation thumbnail
The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients
Associate Professor W. Wongcharoen (Chiang Mai, TH)
Abstract Slides

Access the full session

Session thumbnail
Renal failure and cardiovascular disease 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources